RxDoctor Payments Data

Milan Jansky, MD

Geriatric Medicine · Tucson, AZNPI 1598748428

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations.

$1,677in general payments, 2019–2025

Across 29 payments — averaging $57.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$388
  • Smith+Nephew$264
  • Abbott$155
  • Biosense Webster, Inc.$147
  • Kerecis Limited$137
  • Stryker$130
  • plus $456 from 7 others

What the payments were for

  • Food & beverage$1,677100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,677 in reported general payments places this provider in the 80th percentile of 75 geriatric medicine providers in Arizona.

See all geriatric medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$15,003
Medicare patients
88
Services billed
400

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin96$139,165
TrulicityDulaglutide87$98,638
EliquisApixaban74$97,771
OzempicSemaglutide49$63,652
MounjaroTirzepatide53$57,670
JanuviaSitagliptin Phosphate35$55,321
FarxigaDapagliflozin Propanediol24$37,043
Tresiba Flextouch U-200Insulin Degludec18$35,616
XareltoRivaroxaban18$23,311
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$21,490
LinzessLinaclotide17$19,933
Bydureon BciseExenatide Microspheres20$17,155
ShingrixVaricella-Zoster Ge/As01b/Pf76$16,773
JanumetSitagliptin Phos/Metformin Hcl11$15,107
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog22$12,189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$124$63,65249 claims
GSKTrelegy Ellipta, Shingrix, Breo Ellipta$28$45,075118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 75 geriatric medicine providers in Arizona.

Other geriatric medicine in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →